Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world settingTakuya Sho, Naoya Sakamoto, Tomoe Shimazaki et al.|JGH Open|2019Cited by 45
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Naoya Sakamoto, Goki Suda et al.|Hepatology Research|2020Cited by 44